A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.
CD3 T-cell engager joins ranks of world’s most expensive cancer treatments
Approval expands indication for acromegaly drug
NIH study examines prescribing patterns
Rate of functional independence nearly twice as high with clot removal versus usual care alone
Newest fluoroquinolone to win agency’s okay
Defendants responsible for ‘unprecedented national tragedy,’ U.S. Attorney says
Largest hospitals will get stronger as smaller ones get weaker, analysts predict
Agency cites manufacturing deficiencies
First pathogen-reduction system for plasma approved in U.S.
Positive Results Reported From Pivotal Trial of SD-809 for Chorea Associated With Huntington’s Disease
Treatment is safe and effective in 12-week study
FEATURED STORIES FROM P&T NOVEMBER 2014
From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash